Mads H Andersen
Overview
Explore the profile of Mads H Andersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kjaer L, Skov V, Larsen M, Boklund T, Andersen M, Kefala M, et al.
Front Oncol
. 2023 May;
13:1176173.
PMID: 37223675
Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN...
2.
Draghi A, Presti M, Jensen A, Chamberlain C, Albieri B, Rasmussen A, et al.
Clin Cancer Res
. 2023 May;
29(19):3937-3947.
PMID: 37126006
Purpose: Impaired MHCI-presentation and insensitivity to immune effector molecules are common features of immune checkpoint blockade (ICB)-resistant tumors and can be, respectively, associated with loss of β2 microglobulin (B2M) or...
3.
Gigoux M, Holmstrom M, Zappasodi R, Park J, Pourpe S, Bozkus C, et al.
Sci Transl Med
. 2022 Jun;
14(649):eaba4380.
PMID: 35704596
The majority of JAK2-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (), resulting in a common carboxyl-terminal mutant fragment (CALR), representing an attractive source of neoantigens for cancer...
4.
Itenov T, Sessler D, Khanna A, Ostrowski S, Johansson P, Erikstrup C, et al.
Ann Intensive Care
. 2021 Apr;
11(1):61.
PMID: 33877463
Background: We aimed to determine if the ABO blood types carry different risks of 30-day mortality, acute kidney injury (AKI), and endothelial damage in critically ill patients with sepsis. This...
5.
Holmstrom M, Novotny G, Petersen J, Aaboe-Jorgensen M, Hasselbalch H, Andersen M, et al.
Leuk Lymphoma
. 2019 Jul;
60(13):3296-3299.
PMID: 31256699
No abstract available.
6.
Holmstrom M, Ahmad S, Klausen U, Bendtsen S, Martinenaite E, Riley C, et al.
Blood Cancer J
. 2019 Jan;
9(2):8.
PMID: 30655510
Mutations in exon 9 of the calreticulin gene (CALR) frequently occur in patients with chronic myeloproliferative neoplasms (MPN). Patients exhibit spontaneous cellular immune responses to epitopes derived from the mutant...
7.
Kjaergaard A, Andersen M, Ladefoged S
Ann Clin Biochem
. 2018 Apr;
55(5):620-621.
PMID: 29635923
No abstract available.
8.
Itenov T, Berthelsen R, Jensen J, Gerds T, Pedersen L, Strange D, et al.
Crit Care Resusc
. 2018 Feb;
20(1):54-60.
PMID: 29458322
Objective: Intensive care unit (ICU) patients with acute kidney injury (AKI) who recover kidney function within 28 days experience less severe chronic kidney impairment and have increased long term survival....
9.
Overgaard N, Frosig T, Jakobsen J, Buus S, Andersen M, Jungersen G
Vaccine
. 2017 Sep;
35(42):5629-5636.
PMID: 28886949
The relationship between the antigen dose and the quality of an immune response generated upon immunization is poorly understood. However, findings show that the immune system is indeed influenced by...
10.
Jensen J, Itenov T, Thormar K, Hein L, Mohr T, Andersen M, et al.
Ann Intensive Care
. 2016 Nov;
6(1):114.
PMID: 27873291
Background: It is unclear whether biomarkers of alveolar damage (surfactant protein D, SPD) or conductive airway damage (club cell secretory protein 16, CC16) measured early after intensive care admittance are...